首页> 美国卫生研究院文献>other >Replanning Criteria and Timing Definition for Parotid Protection-Based Adaptive Radiation Therapy in Nasopharyngeal Carcinoma
【2h】

Replanning Criteria and Timing Definition for Parotid Protection-Based Adaptive Radiation Therapy in Nasopharyngeal Carcinoma

机译:鼻咽癌基于腮腺保护的适应性放射治疗的重新规划标准和时间定义

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The goal of this study was to evaluate real-time volumetric and dosimetric changes of the parotid gland so as to determine replanning criteria and timing for parotid protection-based adaptive radiation therapy in nasopharyngeal carcinoma. Fifty NPC patients were treated with helical tomotherapy; volumetric and dosimetric (D mean, V 1, and D 50) changes of the parotid gland at the 1st, 6th, 11th, 16th, 21st, 26th, 31st, and 33rd fractions were evaluated. The clinical parameters affecting these changes were studied by analyses of variance methods for repeated measures. Factors influencing the actual parotid dose were analyzed by a multivariate logistic regression model. The cut-off values predicting parotid overdose were developed from receiver operating characteristic curves and judged by combining them with a diagnostic test consistency check. The median absolute value and percentage of parotid volume reduction were 19.51 cm3 and 35%, respectively. The interweekly parotid volume varied significantly (p < 0.05). The parotid D mean, V 1, and D 50 increased by 22.13%, 39.42%, and 48.45%, respectively. The actual parotid dose increased by an average of 11.38% at the end of radiation therapy. Initial parotid volume, initial parotid D mean, and weight loss rate are valuable indicators for parotid protection-based replanning.
机译:这项研究的目的是评估腮腺的实时体积和剂量学变化,以便确定鼻咽癌中基于腮腺保护的适应性放射治疗的重新规划标准和时机。五十名鼻咽癌患者接受了螺旋断层扫描治疗;评估腮腺在第1,第6,第11,第16,第21,第26,第31和第33部分的体积和剂量(D平均值,V 1和D 50)变化。通过对重复测量方法的方差分析来研究影响这些变化的临床参数。通过多因素逻辑回归模型分析影响腮腺实际剂量的因素。根据接受者的工作特征曲线得出预测腮腺过量的临界值,并将其与诊断测试一致性检查结合起来进行判断。腮腺减容的中位数绝对值分别为19.51 cm 3 和35%。每周两次腮腺体积变化显着(p <0.05)。腮腺D均值,V 1和D 50分别增加22.13%,39.42%和48.45%。放射治疗结束时,实际腮腺剂量平均增加了11.38%。腮腺初始体积,腮腺初始D均值和体重减轻率是基于腮腺保护的重新计划的重要指标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号